single5MG
Semax
5MG Protocol
Semax 5MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks continuous; for 16‑week spans use 6–8 weeks on / 2–4 weeks off cycling
Reconstitution
3.0 mL BAC water
Supports cognitive function, attention, and memory in cerebrovascular/mild cognitive impairment contexts
Neuroprotective properties described in ischemic stroke models with favorable recovery outcomes
Visual-function stabilization described in optic neuropathy studies
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 200 mcg | 12 |
| 2 | Weeks 3–4 | 300 mcg | 18 |
| 3 | Weeks 5–6 | 400 mcg | 24 |
| 4 | Weeks 7–12 | 500 mcg | 30 |
Inject once daily
8–12 weeks continuous; for 16‑week spans use 6–8 weeks on / 2–4 weeks off cycling
Semax is a stabilized ACTH(4–10) analog designed to resist enzymatic degradation and improve central nervous system bioavailability. The protocol describes Semax as modulating neurotrophic signaling (including BDNF-related pathways), supporting neuronal survival, and influencing monoaminergic neurotransmission—mechanisms that align with its use in research on cognition and recovery after neurological insult. The page notes that human studies (largely from Russian clinical literature) commonly use intranasal administration over 10–30 day courses across conditions such as minimal brain dysfunction and cerebrovascular disease. For the purposes of this protocol, subcutaneous administration is presented as an alternative route that may provide more sustained systemic absorption, enabling convenient once-daily dosing in research settings. Mechanistically, the compound is framed as promoting neuroplasticity and neuroprotection rather than acting as a sedative stimulant.
Mild injection-site reactions (redness/minor irritation)
Generally well tolerated
no significant adverse effects reported at standard doses in cited studies
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)